Literature DB >> 24066761

More on JC viremia in natalizumab-treated patients with multiple sclerosis.

Eugene O Major, Elliot Frohman, Daniel Douek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24066761     DOI： 10.1056/NEJMc1308784

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.

Authors:  Spyridon Chalkias; Xin Dang; Evelyn Bord; Marion C Stein; R Philip Kinkel; Jacob A Sloane; Maureen Donnelly; Carolina Ionete; Maria K Houtchens; Guy J Buckle; Stephanie Batson; Igor J Koralnik
Journal:  Ann Neurol       Date:  2014-06-10       Impact factor: 10.422

2.  JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.

Authors:  Elena Uleri; Gabriele Ibba; Claudia Piu; Maurizio Caocci; Stefania Leoni; Giannina Arru; Caterina Serra; GianPietro Sechi; Antonina Dolei
Journal:  J Neurovirol       Date:  2016-11-03       Impact factor: 2.643

3.  JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.

Authors:  Serena Delbue; Francesca Elia; Camilla Carloni; Valentina Pecchenini; Diego Franciotta; Matteo Gastaldi; Elena Colombo; Lucia Signorini; Silvia Carluccio; Anna Bellizzi; Roberto Bergamaschi; Pasquale Ferrante
Journal:  J Neurovirol       Date:  2014-07-23       Impact factor: 2.643

4.  Antibodies reacting with JCPyV_VP2 _167-15mer as a novel serological marker for JC polyomavirus infection.

Authors:  Ole Lagatie; Tom Van Loy; Luc Tritsmans; Lieven J Stuyver
Journal:  Virol J       Date:  2014-10-01       Impact factor: 4.099

5.  Antibody escape by polyomavirus capsid mutation facilitates neurovirulence.

Authors:  Matthew D Lauver; Daniel J Goetschius; Colleen S Netherby-Winslow; Katelyn N Ayers; Ge Jin; Daniel G Haas; Elizabeth L Frost; Sung Hyun Cho; Carol M Bator; Stephanie M Bywaters; Neil D Christensen; Susan L Hafenstein; Aron E Lukacher
Journal:  Elife       Date:  2020-09-17       Impact factor: 8.140

6.  Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 2: From the National Multiple Sclerosis Society Case Conference Proceedings.

Authors:  Roberto Alejandro Cruz; Nick Hogan; Jayne Sconzert; Megan Sconzert; Eugene O Major; Robert P Lisak; Esther Melamed; Thomas C Varkey; Ethan Meltzer; Andrew Goodman; Oleg Komogortsev; Matthew S Parsons; Kathleen Costello; Jennifer S Graves; Scott Newsome; Scott S Zamvil; Elliot M Frohman; Teresa C Frohman
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-12-15

Review 7.  Biology of Polyomavirus miRNA.

Authors:  Wei Zou; Michael J Imperiale
Journal:  Front Microbiol       Date:  2021-04-06       Impact factor: 5.640

8.  Circulating human microRNAs are not linked to JC polyomavirus serology or urinary viral load in healthy subjects.

Authors:  Ole Lagatie; Tom Van Loy; Luc Tritsmans; Lieven J Stuyver
Journal:  Virol J       Date:  2014-03-03       Impact factor: 4.099

9.  Viral miRNAs in plasma and urine divulge JC polyomavirus infection.

Authors:  Ole Lagatie; Tom Van Loy; Luc Tritsmans; Lieven J Stuyver
Journal:  Virol J       Date:  2014-09-02       Impact factor: 4.099
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.